New hope for tough lymphoma: experimental drug targets resistant cancers
Disease control
Recruiting now
This study tests a new drug called CHO-H01, alone or combined with lenalidomide, in people with a type of blood cancer called Non-Hodgkin lymphoma that has returned or not improved with standard treatments. The first part finds a safe dose, and the second part checks if the combi…
Phase: PHASE1, PHASE2 • Sponsor: Cho Pharma Inc. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC